Herbal Formula Science (대한한의학방제학회지)

The Korean Medicine Society for the Herbal Formula Study (대한한의학방제학회)
권호 표지
DOI QR코드

DOI QR Code

Inhibitory Effects on Bone Resorption and osteoblast proliferation of Kyungok-go

경옥고와 경옥고가연자육의 조골세포 증식과 골흡수 억제효과

  • Kim, Ju-Ho (Dept. of Oriental Pharmacy, College of Pharmacy, Won-Kwang Oriental Medicines Research Institute, Won-Kwang University) ;
  • Lee, Jung-Ho (Dept. of Natural Health Management, Song-Ho College) ;
  • Oh, Jae-Min (Dept. of Anatomy, School of Medicine, and Won-Kwang Medical Science Institute, Won-Kwang University) ;
  • Kim, Yun-Kyung (Dept. of Oriental Pharmacy, College of Pharmacy,Won-Kwang Oriental Medicines Research Institute, Won-Kwang University)
  • 김주호 (원광대학교 약학대학 한약학과.원광한약연구소) ;
  • 이정호 (송호대학 자연건강관리학과) ;
  • 오재민 (원광대학교 의과대학 해부학교실.의과학 연구소) ;
  • 김윤경 (원광대학교 약학대학 한약학과.원광한약연구소)
  • Received : 2011.11.18
  • Accepted : 2011.12.21
  • Published : 2011.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : Kyungok-go(KOG), the first herbal formulation of donguibogam, has been used for treating of many symptoms of yin deficiency. In this study, we examined the effect of KOG on bone resorption. Methods : We determined the effects of water extract of KOG in RANKL(Receptor Activator for Nuclear Factor ${\kappa}B$ Ligand)-induced osteoclast differentiation culture system and osteoblast proliferation. In addition, we determined the effects of water extract of ABR on LPS-induced bone-loss with mice. Results : Water extract of KOG showed proliferation effect on osteoblast without cytotoxicity and no effect on RANKL-treated osteoclast differentiation. KOG rescued bone erosion by LPS induction in vivo study. Conclusions : These results demonstrated that KOG can be a useful remedy for treating of bone-loss disease such as osteoporosis.

Keywords

References

  1. 통계청. 2010 인구주택총조사(http://www.census.go.kr/)
  2. National Osteoporosis Foundation. America's Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation. Washington, DC:National Osteoporosis Foundation. 2002.
  3. Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone. 2006;38:S4-S9.
  4. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22:465-75. https://doi.org/10.1359/jbmr.061113
  5. Alliston T, Derynck R. Interfering with bone remodelling. Nature. 2002;416:686-7. https://doi.org/10.1038/416686a
  6. Boyle, W.J., Simonet, W.S., Lacey, D.L.. Osteoclast differentiation and activation. Nature. 2003;423:337-42. https://doi.org/10.1038/nature01658
  7. Yagi, M., Miyamoto, T., Toyama, Y., Suda, T. Role of DC-STAMP in cellular fusion of osteoclasts and macrophage giant cells. J. Bone Miner. Metab. 2006;24:355-8. https://doi.org/10.1007/s00774-006-0697-9
  8. Chesnut CH III, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241-9. https://doi.org/10.1359/JBMR.040325
  9. Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroidinduced osteoporosis: results from a long-term comparative study. Osteoporos Int. 2003;14:801-7. https://doi.org/10.1007/s00198-003-1425-0
  10. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation(MORE) Investigators JAMA. 1999;282:637-45. https://doi.org/10.1001/jama.282.7.637
  11. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY. Effect of parathyroid hormone(1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-41. https://doi.org/10.1056/NEJM200105103441904
  12. Kwak HB, Kim JH, Kim DJ, Kwon YM, Oh JM, Kim YK. Effect of Water Extract of Deer Antler in Osteoclast Differentiation. Korean J. Oriental Physiology & Pathology. 2008;22(4): 891-5.
  13. Park CK, Kim HJ, Kwak HB, Lee TH, Bang MH, Kim CM, Lee Y, Chung DK, Baek NI, Kim J, Lee ZH, Kim HH. Inhibitory effects of Stewartia koreana on osteoclast differentiation and bone resorption. International Immunopharmacology. 2007;7:1507-16. https://doi.org/10.1016/j.intimp.2007.07.016
  14. Han KY, Yang D, Chang EJ, Lee Y, Hao Huang, Sung SH, Lee ZH, Kim YC, Kim HH. Inhibition of osteoclast differentiation and bone resorption by sauchinone. Biochemical Pharmacology. 2007;74:911-23. https://doi.org/10.1016/j.bcp.2007.06.044
  15. Tsai HY, Lin HY, Fong YC, Wu JB, Chen YF, Tsuzuki, Tang CH. Paeonol inhibits RANKLinduced osteoclastogenesis by inhibiting ERK, p38 and NF-${\kappa}B$ pathway. European Journal of Pharmacology. 2008;588:124-33. https://doi.org/10.1016/j.ejphar.2008.04.024
  16. 李仲梓. 醫宗必讀. 의성당. 1992.
  17. 許浚 저, 동의학연구소 역. 東醫寶鑑, 여강출판사. 1994:1권 27.
  18. 辛民敎, 임상본초학. 영림사. 1997:505.
  19. la Cour B., Molgaard P., and Ti Z.. Traditional Chinese Medicine in treatement of hyperlipidaemia. J Ethnopharmacol. 1995;46(2):125-9. https://doi.org/10.1016/0378-8741(95)01234-5
  20. 이진우, 홍무창, 신민규, 배현수. 연자육의 항우울 효과 및 프로티옴 분석을 통한 기전 연구. 동의생리병리학회지. 2006;20(4):830-43.
  21. 김수오. 허혈성 심근경색 모델에 대한 연자육의 효과 연구. 경희대학교 대학원. 2005.
  22. 김태현. 연자육이 LPS로 유도된 BV2 Microglia cell에서의 nitric oxide 생성에 미치는 영향. 경희대학교 대학원. 2007.
  23. Raisz LG. Local and systemic factors in the pathogenesis of osteoporosis. New Engl. J. Med.. 1988;18(13):818-28.
  24. Garnero P, Delmas PL, et al. New developments in biochemical markers for osteoporosis. Calcif Tissue Int. 1996;54(Supp1):S2-5.
  25. 대한골대사학회. 骨多孔症. 서울:한미의학. 2006:51, 343-8.
  26. 윤상호, 김정구. 폐경후 骨多孔症의 최신 치료. 대한산부회지. 2005;48(4):844-56.
  27. Bhavnani BR, Strickler RC. Menopausal hormone therapy. J. Obstet Gynaecol Can. 2005;27(2):137-62. https://doi.org/10.1016/S1701-2163(16)30186-4
  28. Practice Committee of American Society for Reproductive Medicine. Estrogen and progesteron therapy in postmenopausal women. Fertil Steril. 2008;90(5 Suppl):S88-102.
  29. Yazigi R. etc. Carcinoma of the endometrium in patients treated with tibolone. Gynecol Oncol. 2004;93:568-70. https://doi.org/10.1016/j.ygyno.2004.02.003
  30. 조수인. 熟地黃이 卵巢摘出로 閉經이 誘發된 흰쥐에 미치는 영향. 대한본초학회지. 2005;20(4):61-7.
  31. 정국영 외. 蔘鬚가 卵巢摘出로 誘發된 흰쥐의 骨多孔症에 미치는 영향. 대한본초학회지. 2003;18(4):13-23.
  32. 정국영 외. 人蔘이 卵巢摘出로 誘發된 흰쥐의 骨多孔症예방에 미치는 영향. 대한본초학회지. 2004;19(1):1-11.
  33. 안지영 외. 국내 학술지에 발표된 한약추출물의 골다공증에 대한 효능실험결과 고찰. 대한한의학방제학회지. 2008;16(2):47-69.
  34. 이효정 외. 천연물 추출물의 파골세포 분화억제 효과 검색. 한국식품과학회지. 2005;37(6):997-1004.
  35. 박형무. 최신임상강좌: 폐경여성에서의 식물성에 스트로겐의 효용성. 대한산부학회지. 2007;50(3):389-415.
  36. Ron, G.A., Martin, T.J. Therapeutic approaches to bone diseases. cience. 2000;289:1508-14.
  37. Lloyd, M. Treatment of postmenopausal osteoporosis. The New England Journal of Medicine. 1998;338:736-46. https://doi.org/10.1056/NEJM199803123381107